Advertisement
Canada markets close in 3 hours 54 minutes

  • S&P/TSX

    22,008.49
    +136.53 (+0.62%)
     

  • S&P 500

    5,062.09
    +51.49 (+1.03%)
     

  • DOW

    38,434.15
    +194.17 (+0.51%)
     

  • CAD/USD

    0.7312
    +0.0011 (+0.15%)
     

  • CRUDE OIL

    82.84
    +0.94 (+1.15%)
     

  • Bitcoin CAD

    90,965.40
    +660.79 (+0.73%)
     

  • CMC Crypto 200

    1,432.75
    +17.99 (+1.27%)
     

  • GOLD FUTURES

    2,335.80
    -10.60 (-0.45%)
     

  • RUSSELL 2000

    2,000.43
    +32.96 (+1.68%)
     

  • 10-Yr Bond

    4.5900
    -0.0330 (-0.71%)
     

  • NASDAQ

    15,668.90
    +217.59 (+1.41%)
     

  • VOLATILITY

    16.31
    -0.63 (-3.72%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6834
    -0.0016 (-0.23%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Phathom Pharmaceuticals (PHAT) Surges: Stock Moves 6.9% Higher

Zacks Equity Research
·2 min read

Phathom Pharmaceuticals, Inc. PHAT was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $38.20 to $45.46 in the past one-month time frame.

The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Phathom Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

price chart for PHAT
price chart for PHAT


Investors interested in the Medical - Biomedical and Genetics industry may consider Alimera Sciences, Inc. ALIM, which has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

ADVERTISEMENT

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alimera Sciences, Inc. (ALIM) : Free Stock Analysis Report
 
Phathom Pharmaceuticals, Inc. (PHAT) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research